Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.820
Filtrar
1.
Recurso de Internet en Español | LIS - Localizador de Información en Salud | ID: lis-LISBR1.1-47527

RESUMEN

Sitio web del Ministerio de Salud, con información actualizada sobre el Coronavirus COVID-19 (legislación social y preventiva, qué medidas está tomando el gobierno, qué podemos hacer para cuidarlo, preguntas frecuentes y mucho más


Asunto(s)
Betacoronavirus , Coronavirus , Aislamiento Social , Estrategias de eSalud
2.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-LISBR1.1-47414

RESUMEN

A ACT Promoção da Saúde e outras organizações assinam nota conjunta sobre estudo que sugeriu um suposto efeito protetor da nicotina no combate ao COVID-19. A nota destaca que o estudo em questão não foi revisado por pares e que ao menos um dos autores do estudo já foi financiado no passado pela indústria do tabaco.


Asunto(s)
Tabaquismo , Tabaco , Virus del SRAS , Coronavirus , Nicotina
3.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-LISBR1.1-47415

RESUMEN

Por isso, optamos por fazer uma edição especial, focada principalmente no Covid-19 e nas doenças crônicas não transmissíveis e seus fatores de risco, nossa pauta de trabalho. Conversamos com especialistas para entender por que pessoas que fumam são mais suscetíveis a complicações, quais cuidados devem ser tomados com relação à alimentação e como evitar o sedentarismo em tempos de isolamento social. Também analisamos questões como o congelamento de gastos com a saúde e como isso pode interferir no combate ao coronavírus. Em época em que as fake news se multiplicam, também achamos essencial desmistificar algumas "teorias", como a de que alguns "super alimentos" poderiam ajudar a prevenir a doença (nossos parceiros do Joio e o Trigo já publicaram um ótimo texto sobre isso - e, spoiler, apenas uma alimentação adequada constante pode, de fato, ajudar no funcionamento do sistema imunológico). Mais ao final do boletim, temos também algumas atualizações sobre tópicos não relacionados com o Covid-19.


Asunto(s)
Coronavirus , Infecciones por Coronavirus
4.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-LISBR1.1-47350

RESUMEN

Apresenta recursos computacionais e cientistas de dados da Plataforma de Ciências de Dados aplicada à Saúde do Laboratório de Informação em Saúde do ICICT da Fiocruz, hospedada no Laboratório Nacional de Computação Científica.


Asunto(s)
Coronavirus , Infecciones por Coronavirus/mortalidad , Factores de Riesgo
5.
J Korean Med Sci ; 35(18): e174, 2020 May 11.
Artículo en Inglés | MEDLINE | ID: mdl-32383370

RESUMEN

Initially, acute loss of smell (anosmia) and taste (ageusia) was not considered important symptoms for coronavirus disease 2019 (COVID-19). To determine the prevalence of these symptoms and to evaluate their diagnostic significance, we (approximately 150 physicians of the Daegu Medical Association) prospectively collected data of cases of anosmia and ageusia from March 8, 2020, via telephone interview among 3,191 patients in Daegu, Korea. Acute anosmia or ageusia was observed in 15.3% (488/3,191) patients in the early stage of COVID-19 and in 15.7% (367/2,342) patients with asymptomatic-to-mild disease severity. Their prevalence was significantly more common among females and younger individuals (P = 0.01 and P < 0.001, respectively). Most patients with anosmia or ageusia recovered within 3 weeks. The median time to recovery was 7 days for both symptoms. Anosmia and ageusia seem to be part of important symptoms and clues for the diagnosis of COVID-19, particularly in the early stage of the disease.


Asunto(s)
Ageusia/etiología , Infecciones por Coronavirus/complicaciones , Coronavirus , Trastornos del Olfato/etiología , Pandemias , Neumonía Viral/complicaciones , Adulto , Distribución por Edad , Ageusia/epidemiología , Betacoronavirus , Técnicas de Laboratorio Clínico , Coronavirus/genética , Coronavirus/aislamiento & purificación , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/epidemiología , Femenino , Humanos , Masculino , Trastornos del Olfato/epidemiología , Neumonía Viral/epidemiología , Reacción en Cadena de la Polimerasa , Prevalencia , República de Corea/epidemiología , Distribución por Sexo , Olfato , Gusto
6.
J Korean Med Sci ; 35(18): e176, 2020 May 11.
Artículo en Inglés | MEDLINE | ID: mdl-32383371

RESUMEN

The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV-2 and neutralize its aggressive actions on multiple organ systems. Protective cross-reactivity of antibodies against measles and other known viral infections has been postulated, primarily as a result of the initial observations of asymptomatic and mild COVID-19 in children. Uncontrolled case series have demonstrated virus-neutralizing effect of convalescent plasma, supporting its efficiency at early stages of contracting SARS-CoV-2. Given the variability of the virus structure, the utility of convalescent plasma is limited to the geographic area of its preparation, and for a short period of time. Intravenous immunoglobulin may also be protective in view of its nonspecific antiviral and immunomodulatory effects. Finally, human monoclonal antibodies may interact with some SARS-CoV-2 proteins, inhibiting the virus-receptor interaction and prevent tissue injury. The improved understanding of the host antiviral responses may help develop safe and effective immunotherapeutic strategies against COVID-19 in the foreseeable future.


Asunto(s)
Infecciones por Coronavirus/terapia , Coronavirus , Inmunoglobulinas Intravenosas/uso terapéutico , Neumonía Viral/terapia , Anticuerpos Antivirales/sangre , Betacoronavirus , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/epidemiología , Humanos , Inmunización Pasiva , Pandemias , Neumonía Viral/epidemiología
9.
Euro Surveill ; 25(18)2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32400358

RESUMEN

An exponential growth model was fitted to critical care admissions from two surveillance databases to determine likely coronavirus disease (COVID-19) case numbers, critical care admissions and epidemic growth in the United Kingdom before the national lockdown. We estimate, on 23 March, a median of 114,000 (95% credible interval (CrI): 78,000-173,000) new cases and 258 (95% CrI: 220-319) new critical care reports, with 527,000 (95% CrI: 362,000-797,000) cumulative cases since 16 February.


Asunto(s)
Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/transmisión , Coronavirus/aislamiento & purificación , Cuidados Críticos/estadística & datos numéricos , Notificación de Enfermedades/estadística & datos numéricos , Admisión del Paciente/estadística & datos numéricos , Neumonía Viral/diagnóstico , Neumonía Viral/transmisión , Síndrome Respiratorio Agudo Grave/transmisión , Betacoronavirus , Técnicas de Laboratorio Clínico , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/virología , Brotes de Enfermedades , Monitoreo Epidemiológico , Femenino , Humanos , Incidencia , Masculino , Modelos Teóricos , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/virología , Vigilancia de la Población , Síndrome Respiratorio Agudo Grave/diagnóstico , Síndrome Respiratorio Agudo Grave/epidemiología , Síndrome Respiratorio Agudo Grave/virología , Reino Unido/epidemiología
11.
Euro Surveill ; 25(18)2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32400361

RESUMEN

For 45 African countries/territories already reporting COVID-19 cases before 23 March 2020, we estimate the dates of reporting 1,000 and 10,000 cases. Assuming early epidemic trends without interventions, all 45 were likely to exceed 1,000 confirmed cases by the end of April 2020, with most exceeding 10,000 a few weeks later.


Asunto(s)
Infecciones por Coronavirus , Coronavirus , Brotes de Enfermedades , Pandemias , Neumonía Viral , África/epidemiología , Betacoronavirus , China/epidemiología , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/transmisión , Predicción , Humanos , Modelos Estadísticos , Mortalidad , Neumonía Viral/epidemiología , Neumonía Viral/transmisión , Factores de Tiempo
12.
Euro Surveill ; 25(18)2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32400362

RESUMEN

Data on features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children and adolescents are scarce. We report preliminary results of an Italian multicentre study comprising 168 laboratory-confirmed paediatric cases (median: 2.3 years, range: 1 day-17.7 years, 55.9% males), of which 67.9% were hospitalised and 19.6% had comorbidities. Fever was the most common symptom, gastrointestinal manifestations were frequent; two children required intensive care, five had seizures, 49 received experimental treatments and all recovered.


Asunto(s)
Enfermedad Crónica/epidemiología , Coinfección/epidemiología , Infecciones por Coronavirus/diagnóstico , Coronavirus/aislamiento & purificación , Pandemias/prevención & control , Neumonía Viral/diagnóstico , Adolescente , Antivirales/uso terapéutico , Betacoronavirus , Niño , Preescolar , Técnicas de Laboratorio Clínico , Coinfección/virología , Comorbilidad , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Diarrea/etiología , Brotes de Enfermedades , Heces/virología , Femenino , Fiebre/etiología , Hospitales Pediátricos , Humanos , Huésped Inmunocomprometido , Lactante , Recién Nacido , Italia/epidemiología , Masculino , Ventilación no Invasiva/métodos , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Inhibidores de Proteasas/uso terapéutico , Estudios Retrospectivos , Síndrome Respiratorio Agudo Grave/diagnóstico , Síndrome Respiratorio Agudo Grave/epidemiología , Síndrome Respiratorio Agudo Grave/terapia , Resultado del Tratamiento
13.
Euro Surveill ; 25(17)2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32372753

RESUMEN

Using data on coronavirus disease (COVID-19) cases in Germany from the Robert Koch Institute, we found a relative increase with time in the prevalence in 15-34 year-olds (particularly 20-24-year-olds) compared with 35-49- and 10-14-year-olds (we excluded older and younger ages because of different healthcare seeking behaviour). This suggests an elevated role for that age group in propagating the epidemic following the introduction of physical distancing measures.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Coronavirus , Pandemias , Neumonía Viral/epidemiología , Adolescente , Adulto , Distribución por Edad , Betacoronavirus , Niño , Brotes de Enfermedades , Alemania/epidemiología , Humanos , Persona de Mediana Edad , Prevalencia , Distancia Social , Adulto Joven
15.
BMC Infect Dis ; 20(1): 329, 2020 May 07.
Artículo en Inglés | MEDLINE | ID: mdl-32381073

RESUMEN

BACKGROUND: Although people of all ages are susceptible to the novel coronavirus infection, which is presently named "Coronavirus Disease 2019" (COVID-19), there has been relatively few cases reported among children. Therefore, it is necessary to understand the clinical characteristics of COVID-19 in children and the differences from adults. CASE PRESENTATION: We report one pediatric case of COVID-19. A 14-month-old boy was admitted to the hospital with a symptom of fever, and was diagnosed with a mild form of COVID-19. The child's mother and grandmother also tested positive for SARS-CoV-2 RNA. However, the lymphocyte counts were normal. The chest computed tomography (CT) revealed scattered ground glass opacities in the right lower lobe close to the pleura and resorption after the treatment. The patient continued to test positive for SARS-CoV-2 RNA in the nasopharyngeal swabs and stool at 17 days after the disappearance of symptoms. CONCLUSION: The present pediatric case of COVID-19 was acquired through household transmission, and the symptoms were mild. Lymphocyte counts did not significantly decrease. The RNA of SARS-CoV-2 in stool and nasopharyngeal swabs remained positive for an extended period of time after the disappearance of symptoms. This suggests that attention should be given to the potential contagiousness of pediatric COVID-19 cases after clinical recovery.


Asunto(s)
Infecciones por Coronavirus/diagnóstico , Coronavirus , Heces/virología , Fiebre/etiología , Pulmón/diagnóstico por imagen , Nasofaringe/virología , Neumonía Viral/diagnóstico por imagen , Adulto , Betacoronavirus , Técnicas de Laboratorio Clínico , Coronavirus/genética , Coronavirus/aislamiento & purificación , Infecciones por Coronavirus/diagnóstico por imagen , Infecciones por Coronavirus/epidemiología , Composición Familiar , Humanos , Lactante , Recuento de Linfocitos , Masculino , Pandemias , Neumonía Viral/epidemiología , Reacción en Cadena de la Polimerasa , Síndrome Respiratorio Agudo Grave/transmisión , Tomografía Computarizada por Rayos X
16.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue ; 32(3): 269-274, 2020 03.
Artículo en Chino | MEDLINE | ID: mdl-32385985

RESUMEN

The outbreak of coronavirus disease 2019 (COVID-19) is serious and there is no effective treatment to date. In order to reduce the mortality of severe and critical COVID-19, experts from the first-line in related fields in China were organized to analyze, discuss and summarize the diagnosis and treatment of severe and critical COVID-19 patients in Wuhan and other severe epidemic areas, and formulate the expert consensus. The first edition was released on February 22, 2020, and the revised one on March 4, 2020.


Asunto(s)
Infecciones por Coronavirus/diagnóstico , Neumonía Viral/diagnóstico , Betacoronavirus , China , Consenso , Coronavirus , Infecciones por Coronavirus/terapia , Humanos , Pandemias , Neumonía Viral/terapia
17.
Artículo en Inglés | MEDLINE | ID: mdl-32392880

RESUMEN

COVID-19 is an infectious disease caused by a novel coronavirus, which first appeared in China in late 2019, and reached pandemic distribution in early 2020. The first major outbreak in Europe occurred in Northern Italy where it spread to neighboring countries, notably to Austria, where skiing resorts served as a main transmission hub. Soon, the Austrian government introduced strict measures to curb the spread of the virus. Using publicly available data, we assessed the efficiency of the governmental measures. We assumed an average incubation period of one week and an average duration of infectivity of 10 days. One week after the introduction of strict measures, the increase in daily new cases was reversed, and the reproduction number dropped. The crude estimates tended to overestimate the reproduction rate in the early phase. Publicly available data provide a first estimate about the effectiveness of public health measures. However, more data are needed for an unbiased assessment.


Asunto(s)
Infecciones por Coronavirus/diagnóstico , Coronavirus , Brotes de Enfermedades/prevención & control , Pandemias/prevención & control , Neumonía Viral/diagnóstico , Salud Pública , Austria/epidemiología , Betacoronavirus , Coronavirus/aislamiento & purificación , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/transmisión , Humanos , Neumonía Viral/epidemiología , Neumonía Viral/transmisión , Factores de Tiempo
20.
Artículo en Inglés | MEDLINE | ID: mdl-32397262

RESUMEN

Governments and clinicians that were fully involved in the dramatic SARS-CoV-2 outbreak during the last few weeks in Italy (and more or less all over the world) are fiercely debating the use of methods for screening this viral infection. Thus, all countries are employing a lot of resources in order to test more and more subjects. For this purpose, there are different strategies, based on either direct or indirect tests. Among the first category, the main assays used for SARS-CoV-2 are based on a real-time reverse transcriptase polymerase chain reaction (RT-PCR). Such tests can be performed on nasopharyngeal and oropharyngeal swabs for the categories of those with symptoms and those potentially exposed. In order to integrate the molecular assays in the diagnosis of SARS-CoV-2, a wide range of serology immunoassays (IAs) have also been developed. If we want to identify "immune" people in order to let them to come back to work, serology is the best (and probably the only) approach.


Asunto(s)
Técnicas de Laboratorio Clínico/métodos , Infecciones por Coronavirus/diagnóstico , Coronavirus/genética , Cavidad Nasal/virología , Nasofaringe/virología , Neumonía Viral/diagnóstico , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Betacoronavirus , Coronavirus/aislamiento & purificación , Infecciones por Coronavirus/epidemiología , Brotes de Enfermedades , Humanos , Italia/epidemiología , Pandemias , Neumonía Viral/epidemiología , ARN Viral/análisis , Síndrome Respiratorio Agudo Grave/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA